8 October 2026
Editas upgraded at Wells Fargo as Australia approves gene editing trial
Editas Medicine (EDIT) traded higher on Thursday after Australian authorities cleared a Phase 1/2 trial for the company’s gene-editing therapy EDIT-401, and Wells Fargo upgraded the biotech to...
About this report
This article contains independently written commentary and community perspective from Downunder Voices.
Join our community
Follow Downunder Voices
Join thousands of readers following news and community stories from Australia, New Zealand and the Pacific.



